Retatrutide, a groundbreaking dual-acting glucose-regulated incretin analog, represents a significant progression in peptide therapeutics for the handling of type 2 diabetes and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor stimulant and a GIP receptor activator, offer